Developer docs
API playgroundTry for free, no card

Search company profiles

Morphosis Capital

Full company profile

uuid0000yip

Namestring
Morphosis Capital
Legal namestring
Morphosis Capital SRL
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Morphosis Capital is a founder-centric regional private equity firm established in December 2018 by four Romanian entrepreneurs — Simona Gemeneanu, Andrei Gemeneanu (Managing Partner), Dragoș Petre (Partner & CFO), and Gabriela Dumitru. The firm invests growth capital of €10-15 million per transaction into SMEs in Romania and broader Central and Eastern Europe (Bulgaria, Croatia, Czechia, Poland, Slovakia), targeting companies with €1-5 million EBITDA across healthcare, technology, niche manufacturing, consumer/retail, and B2B services. It operates two institutional-grade funds: Fund I (€50M committed, December 2018) and Fund II (€130M committed, closed September 2025), with combined committed capital exceeding €180M and anchor backing from EIF, EBRD, and IFC.

The firm offers both minority and majority equity structures, with operating support in marketing, sales, M&A, HR, and management rather than purely financial capital. The current active portfolio comprises eight companies — Echo Elderly Care (senior care platform launched December 2025), EnduroSat (Bulgarian space infrastructure, invested February 2025), Romania Education Alliance (K12 platform, January 2024), Medima (medical imaging), EMI Group (industrial access systems), Cronos Med (aesthetic medicine), and Stay Fit Gym (fitness) — supported by a team of approximately 11 investment professionals. Three full exits have been completed: Dr. Leahu Dental Clinics to Regina Maria (June 2023), DocProcess to AGENA3000 (September 2025), and La Cocos to Schwarz Group (March 2026), with Fund I having achieved a 30%+ IRR.

Morphosis generates revenue through traditional PE fund-management economics: management fees charged on committed capital and carried interest on exits above the hurdle rate. The firm's legal entities are Morphosis Capital Partners B.V. (registered in The Hague, Netherlands) and Morphosis Capital Fund I Coöperatief U.A. (Amsterdam, Netherlands), while investment activity is concentrated in Romania. Deal flow is sourced primarily through direct founder networks, referrals, and institutional co-investor relationships rather than open deal auctions, and the firm has executed 13 bolt-on acquisitions across its portfolio between 2021 and 2023 to support buy-and-build consolidation strategies in fragmented CEE markets.

Short descriptiontext

Morphosis Capital is a founder-centric Romanian private equity firm operating two institutional funds (€50M Fund I, €130M Fund II) that invest €10-15 million growth tickets into SMEs with €1-5 million EBITDA across healthcare, technology, niche manufacturing, consumer/retail, and B2B services in Romania and Central/Eastern Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersThe Hague, Netherlands
HQ citystring
The Hague
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
private equity investing, growth capital funds, SME buyouts, portfolio management, founder-led partnerships
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Private Equity
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Private Equity Fund Management
TypeManaged Services
Description

Morphosis Capital generates returns through management fees (typically charged on committed capital) and carried interest (share of profits above hurdle rate from successful portfolio company exits). The fund's revenue is tied to investment performance and successful exits from portfolio companies.

morphosiscapital.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Others, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Echo Elderly Care
Description

National platform for high-quality elderly care and active aging services, created through strategic acquisitions and greenfield investments.

morphosiscapital.com
+1 more record
Core offering1 text field

Morphosis Capital manages two regional private equity funds (Fund I €50M, Fund II €130M) that deploy €5–15 million tickets of growth capital into SMEs with EBITDA of €1–5 million in Romania and Central/Eastern Europe. The firm acquires both minority and majority equity stakes in healthcare, technology, niche manufacturing, consumer/retail and B2B services companies and provides hands-on operational support in sales, marketing, M&A, HR and international expansion.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 30%+ IRR achieved by Fund I
+4 more records
Product overview1 text field

Morphosis Capital is a founder-centric regional private equity firm operating two investment funds: Morphosis Capital Fund I (€50M, established 2018) and Morphosis Capital Fund II (€130M, launched 2024). The funds invest in high-growth SMEs across Romania and Central Europe, focusing on healthcare, technology, niche manufacturing, consumer products/retail, and B2B services. Fund I targets companies with EBITDA over €0.5M, deploying €5-15M tickets, while Fund II targets EBITDA of €1-5M with €10-15M investments. The current portfolio includes 8 companies: Echo Elderly Care (elderly care platform), EnduroSat (satellite services), Romania Education Alliance (education), Medima (medical imaging), EMI (industrial access systems), Cronos Med (aesthetic medicine), and Stay Fit Gym (fitness). Previous investments exited include DocProcess, Dr. Leahu Dental Clinics, and La Cocos.

Product and service2 records
1Morphosis Capital Fund I
CategoryPrivate Equity Fund
Description

A €50 million regional private equity fund that invests equity capital (€5–15 million per company) in high-growth Romanian SMEs with EBITDA between €0.5M and €5M, targeting healthcare, technology, niche manufacturing and B2B services. Designed for entrepreneurial founders seeking growth capital plus operational support.

2Morphosis Capital Fund II
CategoryPrivate Equity Fund
Description

A €130 million growth capital private equity fund investing in Romanian and Central/Eastern European SMEs with EBITDA of €1–5 million, deploying €10–15 million equity tickets across healthcare, B2B services, consumer products/retail and niche manufacturing sectors.

Scale indicator23 records

Each record includes

Type, Value, Description, Source

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest dedicated CEE private equity firm (multi-billion AUM), investing in growth and buyouts across Central Europe. Overlap with Morphosis on CEE focus and growth-stage tickets makes it a benchmark incumbent peer.

TypeDirect peer
Description

CEE-focused private equity firm executing mid-market buyouts and growth investments in Romania, Poland, and broader CEE. Closest pure-play competitor to Morphosis given similar geography, ticket size, and sector breadth.

TypeDirect peer
Description

Central European growth equity firm focused on SMEs with €5-25M tickets across tech-enabled services, healthcare, and B2B. Directly comparable to Morphosis in CEE SME growth-equity positioning.

TypeDirect peer
Description

Polish/CEE private equity manager with a 30+ year track record investing in mid-market growth and buyouts in Romania, Poland, and the Baltic region. Direct overlap in geography, ticket size, and founder-led SME thesis.

TypeDirect peer
Description

Southeast European growth capital firm investing in SMEs in Romania, Bulgaria, and the Balkans. Highly comparable business model, ticket size range, and sector focus to Morphosis.

TypeDirect peer
Description

Polish private equity firm deploying mid-market tickets into CEE SMEs. Morphosis's documented co-investor in EMI Group, indicating active operational overlap and shared deal-sourcing network.

TypeDirect peer
Description

Growth equity firm focused exclusively on SMEs in Central and Eastern Europe. Co-invested with Morphosis in La Cocos, and operates an adjacent CEE SME growth mandate.

TypeDirect peer
Description

Growth equity firm investing €5-25M tickets into SMEs across emerging Europe, with an evolving Europe mandate. Morphosis's co-investor in Medima Health and operates in a near-identical strategy.

9Argus Capital Group
TypeRegional player
Description

Romanian-domiciled private equity firm investing in Romanian SMEs. Comparable founder-centric SME thesis but with a more Romania-only focus than Morphosis's emerging CEE scope.

TypeRegional player
Description

Romanian private equity fund-of-funds and co-investment platform with dedicated activity in Romanian SMEs. Adjacent ecosystem participant sharing deal-flow networks with Morphosis in Romania.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries10 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Morphosis Capital

Private Equitymorphosiscapital.com

Morphosis Capital is a founder-centric Romanian private equity firm operating two institutional funds (€50M Fund I, €130M Fund II) that invest €10-15 million growth tickets into SMEs with €1-5 million EBITDA across healthcare, technology, niche manufacturing, consumer/retail, and B2B services in Romania and Central/Eastern Europe.

What Morphosis Capital does

Morphosis Capital is a founder-centric regional private equity firm established in December 2018 by four Romanian entrepreneurs — Simona Gemeneanu, Andrei Gemeneanu (Managing Partner), Dragoș Petre (Partner & CFO), and Gabriela Dumitru. The firm invests growth capital of €10-15 million per transaction into SMEs in Romania and broader Central and Eastern Europe (Bulgaria, Croatia, Czechia, Poland, Slovakia), targeting companies with €1-5 million EBITDA across healthcare, technology, niche manufacturing, consumer/retail, and B2B services. It operates two institutional-grade funds: Fund I (€50M committed, December 2018) and Fund II (€130M committed, closed September 2025), with combined committed capital exceeding €180M and anchor backing from EIF, EBRD, and IFC.

The firm offers both minority and majority equity structures, with operating support in marketing, sales, M&A, HR, and management rather than purely financial capital. The current active portfolio comprises eight companies — Echo Elderly Care (senior care platform launched December 2025), EnduroSat (Bulgarian space infrastructure, invested February 2025), Romania Education Alliance (K12 platform, January 2024), Medima (medical imaging), EMI Group (industrial access systems), Cronos Med (aesthetic medicine), and Stay Fit Gym (fitness) — supported by a team of approximately 11 investment professionals. Three full exits have been completed: Dr. Leahu Dental Clinics to Regina Maria (June 2023), DocProcess to AGENA3000 (September 2025), and La Cocos to Schwarz Group (March 2026), with Fund I having achieved a 30%+ IRR.

Morphosis generates revenue through traditional PE fund-management economics: management fees charged on committed capital and carried interest on exits above the hurdle rate. The firm's legal entities are Morphosis Capital Partners B.V. (registered in The Hague, Netherlands) and Morphosis Capital Fund I Coöperatief U.A. (Amsterdam, Netherlands), while investment activity is concentrated in Romania. Deal flow is sourced primarily through direct founder networks, referrals, and institutional co-investor relationships rather than open deal auctions, and the firm has executed 13 bolt-on acquisitions across its portfolio between 2021 and 2023 to support buy-and-build consolidation strategies in fragmented CEE markets.

Morphosis Capital firmographics

Firmographics
Name
Morphosis Capital
Legal name
Morphosis Capital SRL
Website
https://morphosiscapital.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Morphosis Capital is a founder-centric Romanian private equity firm operating two institutional funds (€50M Fund I, €130M Fund II) that invest €10-15 million growth tickets into SMEs with €1-5 million EBITDA across healthcare, technology, niche manufacturing, consumer/retail, and B2B services in Romania and Central/Eastern Europe.
Ownership category
akta.pro rank

Where Morphosis Capital is headquartered

Location

Headquarters

HQ city
The Hague
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

Morphosis Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others, Infrastructure

Revenue model

  1. Private Equity Fund Management: Morphosis Capital generates returns through management fees (typically charged on committed capital) and carried interest (share of profits above hurdle rate from successful portfolio company exits). The fund's revenue is tied to investment performance and successful exits from portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Morphosis Capital product offering

Product offering

Core offering

Morphosis Capital manages two regional private equity funds (Fund I €50M, Fund II €130M) that deploy €5–15 million tickets of growth capital into SMEs with EBITDA of €1–5 million in Romania and Central/Eastern Europe. The firm acquires both minority and majority equity stakes in healthcare, technology, niche manufacturing, consumer/retail and B2B services companies and provides hands-on operational support in sales, marketing, M&A, HR and international expansion.

Product overview

Morphosis Capital is a founder-centric regional private equity firm operating two investment funds: Morphosis Capital Fund I (€50M, established 2018) and Morphosis Capital Fund II (€130M, launched 2024). The funds invest in high-growth SMEs across Romania and Central Europe, focusing on healthcare, technology, niche manufacturing, consumer products/retail, and B2B services. Fund I targets companies with EBITDA over €0.5M, deploying €5-15M tickets, while Fund II targets EBITDA of €1-5M with €10-15M investments. The current portfolio includes 8 companies: Echo Elderly Care (elderly care platform), EnduroSat (satellite services), Romania Education Alliance (education), Medima (medical imaging), EMI (industrial access systems), Cronos Med (aesthetic medicine), and Stay Fit Gym (fitness). Previous investments exited include DocProcess, Dr. Leahu Dental Clinics, and La Cocos.

Differentiator

Problem solved

Functional benefit

Brands

  • Echo Elderly Care: National platform for high-quality elderly care and active aging services, created through strategic acquisitions and greenfield investments.
  • Romania Education Alliance

Products and services

  • Morphosis Capital Fund I A €50 million regional private equity fund that invests equity capital (€5–15 million per company) in high-growth Romanian SMEs with EBITDA between €0.5M and €5M, targeting healthcare, technology, niche manufacturing and B2B services. Designed for entrepreneurial founders seeking growth capital plus operational support.
  • Morphosis Capital Fund II A €130 million growth capital private equity fund investing in Romanian and Central/Eastern European SMEs with EBITDA of €1–5 million, deploying €10–15 million equity tickets across healthcare, B2B services, consumer products/retail and niche manufacturing sectors.

Quantifiable outcome

  • 30%+ IRR achieved by Fund I
  • +4 more outcomes

Companies that use Morphosis Capital

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Morphosis Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Morphosis Capital partnerships and signals

Strategic signal

Scale indicators23 records

Recent moves11 records

Expansion highlights6 records

Morphosis Capital competitors and assessment

Company assessment

Broad incumbents

  • Mid Europa Partners: Largest dedicated CEE private equity firm (multi-billion AUM), investing in growth and buyouts across Central Europe. Overlap with Morphosis on CEE focus and growth-stage tickets makes it a benchmark incumbent peer.

Direct peers

  • Abris Capital Partners: CEE-focused private equity firm executing mid-market buyouts and growth investments in Romania, Poland, and broader CEE. Closest pure-play competitor to Morphosis given similar geography, ticket size, and sector breadth.
  • 3TS Capital Partners: Central European growth equity firm focused on SMEs with €5-25M tickets across tech-enabled services, healthcare, and B2B. Directly comparable to Morphosis in CEE SME growth-equity positioning.
  • Enterprise Investors: Polish/CEE private equity manager with a 30+ year track record investing in mid-market growth and buyouts in Romania, Poland, and the Baltic region. Direct overlap in geography, ticket size, and founder-led SME thesis.
  • BlackPeak Capital: Southeast European growth capital firm investing in SMEs in Romania, Bulgaria, and the Balkans. Highly comparable business model, ticket size range, and sector focus to Morphosis.
  • Innova Capital: Polish private equity firm deploying mid-market tickets into CEE SMEs. Morphosis's documented co-investor in EMI Group, indicating active operational overlap and shared deal-sourcing network.
  • CEECAT Capital: Growth equity firm focused exclusively on SMEs in Central and Eastern Europe. Co-invested with Morphosis in La Cocos, and operates an adjacent CEE SME growth mandate.
  • Integral Venture Partners: Growth equity firm investing €5-25M tickets into SMEs across emerging Europe, with an evolving Europe mandate. Morphosis's co-investor in Medima Health and operates in a near-identical strategy.

Regional players

  • Argus Capital Group: Romanian-domiciled private equity firm investing in Romanian SMEs. Comparable founder-centric SME thesis but with a more Romania-only focus than Morphosis's emerging CEE scope.
  • Catalyst Romania: Romanian private equity fund-of-funds and co-investment platform with dedicated activity in Romanian SMEs. Adjacent ecosystem participant sharing deal-flow networks with Morphosis in Romania.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Morphosis Capital social profiles

Digital presence

Morphosis Capital compliance and trust

Trust signal

Compliance1 record

Morphosis Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Morphosis Capital leadership team

Management profile

Number of profiles

Profiles12 records

Morphosis Capital subsidiaries and ownership

Company hierarchy

Subsidiaries10 records

Morphosis Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Morphosis Capital M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Morphosis Capital

What does Morphosis Capital do?

Morphosis Capital manages two regional private equity funds (Fund I €50M, Fund II €130M) that deploy €5–15 million tickets of growth capital into SMEs with EBITDA of €1–5 million in Romania and Central/Eastern Europe. The firm acquires both minority and majority equity stakes in healthcare, technology, niche manufacturing, consumer/retail and B2B services companies and provides hands-on operational support in sales, marketing, M&A, HR and international expansion.

Is Morphosis Capital a public or private company?

Morphosis Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Morphosis Capital founded?

Morphosis Capital was founded in 2018. It employs 11 to 50 people.

Where is Morphosis Capital based?

Morphosis Capital is headquartered in The Hague, Netherlands, in the Europe region.

How does Morphosis Capital make money?

One revenue line is on record: private Equity Fund Management.

Who are Morphosis Capital's main competitors?

Mid Europa Partners is listed as a broad incumbent. Direct peers are Abris Capital Partners, 3TS Capital Partners, Enterprise Investors, BlackPeak Capital, Innova Capital, CEECAT Capital and Integral Venture Partners. Regional players are Argus Capital Group and Catalyst Romania.

Does Morphosis Capital have an API?

No public API is recorded for Morphosis Capital.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Request BlockedEBRD, CEECAT Capital and Morphosis Capital exit La Cocos investment in RomaniaEBRD, CEECAT Capital, and Morphosis Capital completed their exit from La Cocos, a Romanian discount retailer, after closing a transaction with Schwarz Group. La Cocos generated €298 million in 2025, up from €227 million in 2024, and expanded its store network from three to seven locations. The partnership with Schwarz Group is expected to support accelerated expansion in Romania and potentially internationally.Request BlockedEBRD, CEECAT Capital and Morphosis Capital exit La Cocos investment in RomaniaEBRD, CEECAT Capital, and Morphosis Capital completed their exit from La Cocos, a Romanian discount retailer, after the company was acquired by Schwarz Group. La Cocos had grown from three to seven stores and generated €298 million in 2025 revenues. The partnership with Schwarz is expected to support further expansion in Romania and internationally.Request BlockedEBRD, CEECAT Capital and Morphosis Capital exit La Cocos investment in RomaniaEBRD, CEECAT Capital, and Morphosis Capital completed their exit from La Cocos, a Romanian discount retailer, after Schwarz Group acquired the company. La Cocos had grown from three to seven stores and generated €298 million in 2025. The partnership with Schwarz Group is expected to support accelerated expansion in Romania and potentially internationally.SeeNewsRomania's Morphosis Capital exits Stay Fit GymMorphosis Capital agreed to sell its stake in Stay Fit Gym to 18GYM, backed by Enterprise Investors. The deal is expected to deliver a net multiple of up to 4.6x and an IRR over 40%, concluding a five-year value-creation program. Completion is subject to merger control and foreign direct investment clearance, expected within four months.Request BlockedEBRD, CEECAT Capital and Morphosis Capital exit La Cocos investment in RomaniaAn investor consortium led by EBRD, CEECAT Capital, and Morphosis Capital has completed the sale of their stake in Romania's La Cocos discount retailer to companies of Schwarz Group, marking a full exit approximately one year after their initial investment in August 2024. La Cocos, founded in 2014, has grown from three to seven stores and increased revenues from €227 million in 2024 to €298 million in 2025. The partnership with Schwarz Group is expected to accelerate La Cocos's expansion both domestically and internationally while preserving the company's hypercash model and entrepreneurial culture.AinMorphosis Capital Fund II invests in Romania’s Echo Elderly CareMorphosis Capital Fund II has made an investment in Echo Elderly Care, a Romanian platform focused on developing a national network of high-quality elderly care services. The funding will support the launch and scaling of the platform, including integration of two initial care centers in Otopeni and Sibiu, with plans for national expansion through acquisitions and greenfield projects. The investment is co-supported by Romania Recovery Equity Fund and InvestEU Fund, and marks Morphosis Capital Fund II's fourth investment.Pulse 2.0Morphosis Capital: Fund II Closed at €130 MillionMorphosis Capital Partners closed its second growth capital fund at €130 million, exceeding its original hard cap. The fund, backed by EIF, EBRD, and IFC, will invest €10-15 million per transaction in SMEs with EBITDA of €1-5 million. It has made three investments and expects two to three new deals annually.Request BlockedEBRD commits €15 million to Morphosis Capital Fund IIThe EBRD committed €15 million to Morphosis Capital Fund II, a private equity fund managed by Morphosis Capital Partners, to support SMEs and lower mid-market companies in Romania and Central and Eastern Europe. The investment aims to strengthen equity financing as an alternative to traditional funding sources, with the EBRD having invested over €11.6 billion in 560 projects in Romania.TheRecursive.comEnduroSat Prepares to Enter New Market Segment Securing €20 Million InvestmentEnduroSat secured a €20 million funding round led by CEECAT Capital, with Morphosis Capital joining as a new investor. The funds will expand satellite capacity to enter a new market segment. The company has raised €48 million since 2015 and expects €13.81 million in 2023 revenue.AinBulgarian aerospace company EnduroSat secures €20M led by CEECAT CapitalEnduroSat, a Bulgarian aerospace firm, raised €20 million in a round led by CEECAT Capital, with Morphosis Capital participating. The company has raised €48 million total and serves over 210 customers. It plans to expand into new market segments by increasing satellite sizes.